The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.
作者信息
Ma Qinhai, Qiu Minshan, Zhou Hongxia, Chen Jie, Yang Xue, Deng Zhenxuan, Chen Liping, Zhou Jinchao, Liao Yuping, Chen Qimin, Zheng Qianwei, Cai Lihua, Shen Lihan, Yang Zifeng
机构信息
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, PR China.
Dongguan People's Hospital, Dongguan, 523059, PR China.
出版信息
Pharmacol Res. 2020 Oct;160:105073. doi: 10.1016/j.phrs.2020.105073. Epub 2020 Jul 9.
Abstract
摘要
相似文献
1
The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2.血必净注射液（XBJ）治疗成人新型冠状病毒肺炎重型及危重型的研究及XBJ对严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）的抑制作用
Pharmacol Res. 2020 Oct;160:105073. doi: 10.1016/j.phrs.2020.105073. Epub 2020 Jul 9.
2
Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo.蒲地蓝消炎口服液（PDL）对新型冠状病毒肺炎的体内外治疗效果
Signal Transduct Target Ther. 2020 May 8;5(1):66. doi: 10.1038/s41392-020-0176-0.
3
A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19).治疗药物和中草药抗 SARS-CoV-2（COVID-19）的综述。
Pharmacol Res. 2020 Aug;158:104929. doi: 10.1016/j.phrs.2020.104929. Epub 2020 May 20.
4
Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.探讨 2019 年冠状病毒病：具有抗 SARS-CoV-2 潜在活性的已上市药物的作用机制。
Biochem Pharmacol. 2020 Oct;180:114169. doi: 10.1016/j.bcp.2020.114169. Epub 2020 Jul 23.
5
[Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].[严重急性呼吸综合征冠状病毒2（SARS-CoV-2）：我们应该针对病毒、细胞还是疾病？]
Virologie (Montrouge). 2020 Jun 1;24(3):135-141. doi: 10.1684/vir.2020.0843.
6
The pros and cons of traditional Chinese medicines in the treatment of COVID-19.中药治疗新型冠状病毒肺炎的利弊
Pharmacol Res. 2020 Jul;157:104873. doi: 10.1016/j.phrs.2020.104873. Epub 2020 May 3.
7
Xuebijing injection in the treatment of COVID-19: a retrospective case-control study.血必净注射液治疗新型冠状病毒肺炎：一项回顾性病例对照研究。
Ann Palliat Med. 2020 Sep;9(5):3235-3248. doi: 10.21037/apm-20-1478. Epub 2020 Sep 10.
8
SARS-CoV-2 and COVID-19: What are our options? Where should we focus our attention on to find new drugs and strategies?严重急性呼吸综合征冠状病毒2（SARS-CoV-2）与冠状病毒病2019（COVID-19）：我们有哪些选择？我们应将注意力集中在哪些方面以寻找新药物和新策略？
Travel Med Infect Dis. 2020 Sep-Oct;37:101685. doi: 10.1016/j.tmaid.2020.101685. Epub 2020 Apr 22.
9
Purposing Saikosaponins for the treatment of COVID-19.将柴胡皂苷用于治疗新型冠状病毒肺炎。
Med Hypotheses. 2020 Jul;140:109782. doi: 10.1016/j.mehy.2020.109782. Epub 2020 Apr 23.
10
A multi-center, randomized controlled trial by the Integrative Management in Japan for Epidemic Disease (IMJEDI study-RCT) on the use of Kampo medicine, kakkonto with shosaikotokakikyosekko, in mild-to-moderate COVID-19 patients for symptomatic relief and prevention of severe stage: a structured summary of a study protocol for a randomized controlled trial.一项由日本综合传染病管理（IMJEDI 研究-RCT）开展的多中心、随机对照临床试验，评估了汉方药加味抗感煎剂（kakkonto with shosaikotokakikyosekko）在缓解 COVID-19 轻症和中度患者症状和预防重症方面的作用：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 2;21(1):827. doi: 10.1186/s13063-020-04746-9.
引用本文的文献
1
Treatment effects of Xuebijing injection in patients with sepsis by clinical phenotype: a post hoc analysis of the EXIT-SEP trial.血必净注射液对不同临床表型脓毒症患者的治疗效果：EXIT-SEP试验的事后分析
EClinicalMedicine. 2025 Jul 9;86:103341. doi: 10.1016/j.eclinm.2025.103341. eCollection 2025 Aug.
2
A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With "Long-Covid-19".补肺活血胶囊治疗“长新冠”患者疗效的亚组再分析
Pulm Circ. 2025 Apr 27;15(2):e70084. doi: 10.1002/pul2.70084. eCollection 2025 Apr.
3
Practice and principle of traditional Chinese medicine for the prevention and treatment of COVID-19.中医药防治新冠肺炎的实践与原则
Front Med. 2023 Dec;17(6):1014-1029. doi: 10.1007/s11684-023-1040-8. Epub 2023 Dec 29.
4
Recent advances towards natural plants as potential inhibitors of SARS-Cov-2 targets.天然植物作为 SARS-CoV-2 靶点潜在抑制剂的最新进展。
Pharm Biol. 2023 Dec;61(1):1186-1210. doi: 10.1080/13880209.2023.2241518.
5
Effectiveness and safety of Xuebijing injection for patients with coronavirus disease 2019: a systematic review and Metaanalysis.血必净注射液治疗 2019 冠状病毒病患者的有效性和安全性：系统评价和 Meta 分析。
J Tradit Chin Med. 2023 Aug;43(4):631-639. doi: 10.19852/j.cnki.jtcm.20230517.002.
6
Potential herb‒drug interactions between anti-COVID-19 drugs and traditional Chinese medicine.抗新冠病毒药物与中药之间潜在的药草-药物相互作用。
Acta Pharm Sin B. 2023 Jun 5;13(9):3598-637. doi: 10.1016/j.apsb.2023.06.001.
7
New opportunities and challenges of natural products research: When target identification meets single-cell multiomics.天然产物研究的新机遇与挑战：当靶点识别遇上单细胞多组学
Acta Pharm Sin B. 2022 Nov;12(11):4011-4039. doi: 10.1016/j.apsb.2022.08.022. Epub 2022 Aug 27.
8
Traditional Chinese medicine injections: where we are after 80-year development.中药注射剂：历经80年发展后的现状
Chin Med. 2022 Nov 8;17(1):127. doi: 10.1186/s13020-022-00681-w.
9
Exploring primary healthcare practitioners' experiences regarding the coronavirus disease 2019 (COVID-19) pandemic in KwaZulu-Natal, South Africa.探讨南非夸祖鲁-纳塔尔省初级卫生保健从业者在 2019 年冠状病毒病（COVID-19）大流行期间的经验。
Prim Health Care Res Dev. 2022 Nov 4;23:e67. doi: 10.1017/S1463423622000536.
10
Role of Traditional Chinese Medicine in Treating Severe or Critical COVID-19: A Systematic Review of Randomized Controlled Trials and Observational Studies.中医药在治疗重型或危重型新型冠状病毒肺炎中的作用：随机对照试验和观察性研究的系统评价
Front Pharmacol. 2022 Jul 15;13:926189. doi: 10.3389/fphar.2022.926189. eCollection 2022.
本文引用的文献
1
Pathological findings of COVID-19 associated with acute respiratory distress syndrome.与急性呼吸窘迫综合征相关的新型冠状病毒肺炎的病理表现
Lancet Respir Med. 2020 Apr;8(4):420-422. doi: 10.1016/S2213-2600(20)30076-X. Epub 2020 Feb 18.
2
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
3
A Novel Coronavirus Emerging in China - Key Questions for Impact Assessment.一种在中国出现的新型冠状病毒——影响评估的关键问题
N Engl J Med. 2020 Feb 20;382(8):692-694. doi: 10.1056/NEJMp2000929. Epub 2020 Jan 24.
4
Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.成人社区获得性肺炎诊断和治疗。美国胸科学会和美国传染病学会的官方临床实践指南。
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST.
5
XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial.血必净注射液对比安慰剂治疗重症社区获得性肺炎患者的随机对照试验。
Crit Care Med. 2019 Sep;47(9):e735-e743. doi: 10.1097/CCM.0000000000003842.
6
Treatment effects of xuebijing injection in severe septic patients with disseminated intravascular coagulation.血必净注射液治疗弥漫性血管内凝血严重脓毒症患者的效果。
Evid Based Complement Alternat Med. 2014;2014:949254. doi: 10.1155/2014/949254. Epub 2014 Mar 23.
7
Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study.沙特阿拉伯 47 例中东呼吸综合征冠状病毒病的流行病学、人口统计学和临床特征：描述性研究。
Lancet Infect Dis. 2013 Sep;13(9):752-61. doi: 10.1016/S1473-3099(13)70204-4. Epub 2013 Jul 26.
Zotero 插件